Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction the LoWASA Study

European Heart Journal

Volumn 25, Issue 3, 2004, Pages 232-239

  Herlitz, Johan ^a   Holm, Johan ^b   Peterson, Magnus ^c   Karlson, Björn W ^a   Evander, Maria Haglid ^a   Erhardt, Leif ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Lidkoping Hospital   (Sweden)

Author keywords

Acute myocardial infarction; Prognosis; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HAIR LOSS; HEART DEATH; HEART REINFARCTION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STROKE;

AGED; ANTICOAGULANTS; ASPIRIN; CEREBROVASCULAR ACCIDENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; LONG-TERM CARE; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME; WARFARIN;

EID: 1242294440     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2003.10.026     Document Type: Article

References (18)

1. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999;282:2058-67.
2. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323(3):147-52.
3. Hurlen M, Abdelnoor M, Smith P et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347(13):1019-22.
4. Brouwer MA, van den Bergh PJ, Aengevaeren WR. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: Results of the antithrombotics in the prevention of reocclusion in coronary thrombolysis (APRICOT)-2 Trial. Circulation 2002;106:659-66.
5. van Es RF, Jonker JJC, Verheugt FWA et al. for the Anti-thrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and cournadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002;360:109-13.
6. Cohen M, Adams PC, Parry G et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end point analysis from the ATACS trial. Antithrombotic therapy in Acute Coronary Syndromes Research Group. Circulation 1994;89(1):81-8.
7. Cournadin Aspirin Reinfarction Study (CARS) Investigators. Randomized double-blind trial or fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997;350:389-96.
8. Meade T, Mellows S, Brozovic M et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533-7.
9. Holm J, Hillarp A, Erhardt L et al. Changes in levels of factor VII and protein S after acute myocardial infarction: effects of low dose warfarin. Thromb Res 1999;96:205-12.
10. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet 1998;351:233-41.
11. Bradley JV. Distribution-Free Statistical Test. London, Prentice-Hall (1968) p. 73-80.
12. Anand SS, Yusuf S, Poque J et al. for the OASIS Pilot Study Investigators. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non Q-wave myocardial infarction: Organization to Assess Strategies for Ischemic Syndromes (OASIS) pilot study results. Circulation 1998;98:1064-70.
13. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996;348:633-8.
14. Fiore LD, Ezekowitz MD, Brophy MT et al. for the Combination Hemotherapy and Mortality Prevention (Champ) Study Group. Department of veterans affairs cooperative studies program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction. Circulation 2002; 105:557-63.
15. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and tow-dose anticoagulation on obstructive changes in saphenousvein coronary-artery bypass grafts. N Engl J Med 1997;336:153-62.
16. Knatterud GL, Rosenberg Y, Campeau L et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Circulation 2000;102:157-65.
17. Huynh T, Théroux P, Bogaty P et al. Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation 2001;103:3069-74.
18. Armstrong PW, Fu Y, Chang WC et al. Acute coronary syndromes in the GUSTO-IIb trial. Prognostic insights and impact of recurrent ischemia. Circulation 1998;98:1860-8.